论文部分内容阅读
目的探讨米非司酮在临床上用于绝经期妇女取宫内节育器的应用价值。方法对于我院收治的78例取宫内节育器的绝经期妇女,随机分为两组,实验组40例取宫内节育器前3天口服米非司酮,对照组38例,在取器前不用任何药物。分别观察2组宫颈扩张、疼痛程度和不良反应发生的情况。结果实验组的宫颈扩张明显高于对照组(P<0.01),术中受术者的疼痛程度较对照组轻,不良反应发生率小于对照组。结论在取器前口服米非司酮,可以增加宫颈的扩张,且能减少受术者的痛苦,降低不良反应发生率,在取器时,可适当考虑使用药物,以增加取器的成功率。
Objective To investigate the clinical value of mifepristone in the clinical use of IUD in postmenopausal women. Methods 78 cases of IUD in our hospital were randomly divided into two groups. 40 cases in the experimental group took mifepristone three days before the IUD, 38 cases in the control group, No medication before. Two cases of cervical dilation, pain and adverse reactions were observed. Results The cervical dilatation in the experimental group was significantly higher than that in the control group (P <0.01). The degree of pain in the operation group was lighter than that in the control group and the incidence of adverse reactions was less than that in the control group. Conclusions Oral administration of mifepristone before taking the device can increase the cervical dilatation and reduce the suffering of the patient and reduce the incidence of adverse reactions. When taking the device, the drug may be appropriately considered to increase the success rate of the device .